BeyondSpring to Present at the Jefferies 2017 Healthcare Conference

NEW YORK, June 02, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, announced today that Dr. Lan Huang, Ph.D., Chairman and CEO, will present at the Jefferies 2017 Healthcare Conference on Thursday, June 8, 2017 at 8:00 a.m. Eastern Time. 

A live webcast of the conference call will be available online which can be accessed through the Investors section of BeyondSpring’s website, Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. An archived replay of the webcast will be available on the Company’s website after the conference.

Management will also be available for one-on-one meetings at the Conference. Investors attending the conference who wish to meet with management for a one-on-one meeting should notify their appropriate contact or e-mail

About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and Phase 2/3 clinical trials in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.

About Plinabulin
Studies on Plinabulin's method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to up-regulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.

CONTACT: Investor Relations: 
Garth Russell / Steve Silver
KCSA Strategic Communications
P: +1-212-682-6300 /

Media Relations:
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207 /